glp-1 receptor agonists effectiveness comparison Comparing GLP-type therapies for weight loss in those without diabetes. Two glucagon-like peptide-1 (GLP-1 RAs) (#semaglutide and #liraglutide) and one dual agonist (#tirzepatide) have been FDA-approved for #weightloss in adults Mapping the effectiveness and risks

The gut, it turned out, wasnt just a passive tube for digestion

In rodent and primate metabolic models, amylin analogue administration has been shown to attenuate glucagon-driven hepatic glucose output and reduce postprandial glycemic excursions, independently of insulin secretion (Verchere et al., Proceedings of the National Academy of Sciences, 1996

We leverage multiple mechanisms of action to support complex health challenges and key areas of health and back our finished formulations with peer-reviewed, published clinical research

How do SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors compare in reducing #mortality and #cardiovascular events in patients with type 2 #diabetes

In cardiac models, Bock-Marquette et al., Nature 2004 reported that T4 activates integrin-linked kinase and Akt signalling, promoting cardiomyocyte survival, migration and improved function after coronary ligation in mice

Liraglutide and semaglutide are available in the UK and the U.S